Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials

Published:2013-03-15 Issue:4 Volume:75 Page:919-930
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Qi Wei-Xiang¹,Shen Zan¹,Lin Feng¹,Sun Yuan-jue¹,Min Da-liu¹,Tang Li-Na¹,He Ai-Na¹,Yao Yang¹

Affiliation:

1. Department of Oncology; the Sixth People's Hospital; Shanghai Jiao Tong University; no. 600; Yishan Road; Shanghai; 200233; China

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2125.2012.04417.x/fullpdf

Reference54 articles.

1. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC;Pennell;Oncologist,2009

2. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J Clin Oncol,2012

3. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer;Van Cutsem;J Clin Oncol,2009

4. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Brufsky;J Clin Oncol,2011

5. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401;Kelly;J Clin Oncol,2012

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists;International Journal of Clinical Oncology;2023-03-05

2. Risks and management of hypertension in cancer patients undergoing targeted therapy: a review;Clinical Hypertension;2022-05-15

3. Multimodality Advanced Cardiovascular and Molecular Imaging for Early Detection and Monitoring of Cancer Therapy-Associated Cardiotoxicity and the Role of Artificial Intelligence and Big Data;Frontiers in Cardiovascular Medicine;2022-03-15

4. Nursing Management and Adverse Events in Thyroid Cancer Treatments with Tyrosine Kinase Inhibitors. A Narrative Review;Cancers;2021-11-26

5. Balancing the Risk-Benefit Ratio of Immune Checkpoint Inhibitor and Anti-VEGF Combination Therapy in Renal Cell Carcinoma: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2021-10-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3